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Abstract: As the association of marine animals with bacteria has become more commonly 
recognized, researchers have increasingly questioned whether these animals actually produce 
many of the bioactive compounds originally isolated from them. Bacteriocins, ribosomally 
synthesized antibiotic peptides, constitute one of the most potent weapons to fight against 
pathogen infections. Indeed, bacteriocinogenic bacteria may prevent pathogen 
dissemination by occupying the same  ecological niche. Bacteriocinogenic strains 
associated with marine animals  are  a relevant source for isolation  of probiotics. This 
review draws up an inventory of the marine bacteriocinogenic strains isolated from animal-
associated microbial communities, known to date. Bacteriocin-like inhibitory substances 
(BLIS) and fully-characterized bacteriocins are described. Finally, their applications as 
probiotics in aquaculture are discussed. 
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Abbreviations:  APD2: Antimicrobial peptide database 2; BLIS:  Bacteriocin-like 
inhibitory substance; FDA: Food and Drug Administration; GRAS: Generally recognize as 
safe; LAB: Lactic acid bacteria 
 
1. Introduction 
According to a FAO report, the average consumption of aquaculture products relative to total per 
capita fish for human consumption rose from 14% in 1986 to 47% in 2006 and it can be expected to 
reach 50% in the next few years. However, the development of aquaculture farming will have to be 
backed up with appropriately relevant  management  practices, in  particular by decreasing its 
environmental impact and limiting the  associated  infectious epizooties. Indeed, as in all animal 
industries, development and intensification generate higher population densities  which  exacerbate 
disease processes, leading to stock mortality [1]. Major economic losses in cultured fish worldwide 
result from a relatively small number of opportunistic pathogens bacteria [2]. Vibrio is one of the most 
important pathogenic recognized in larval cultures, provoking a high mortality [3,4]. Furthermore, fear 
of aquaculture farming increases with climate change. Indeed, a recent report has shown that numerous 
bacteria display greater virulence at higher temperatures due to reduced  resistance  and increased 
virulence and transmission [5]. At the same time, use of prophylactic antibiotics is detrimental to 
aquatic and terrestrial environments, animal and human health [6,7]. That’s why authorities such as the 
European Authority have chosen to limit antibiotic use as a curative situation. In this context, scientific 
communities have proposed friendly alternatives such as vaccines [1], antibiotic substitutes [8] or use 
of probiotic [9]. Bacteriocinogenic bacterial strains appear to be an excellent candidate for a friendly 
alternative since bacteriocin would be used as an antibiotic substitute [10], whereas bacteria would be 
a potential probiotic [11].  
Bacteriocins are ribosomally synthesized proteinaceous compounds, lethal to bacteria closely 
related to the producing bacteria [10,12], the latter being protected by an immunity phenomenon. The 
role of bacteriocins in microbial communities hasn’t been well-established yet. Bacteriocins may serve 
as anti-competitor compounds enabling an invasion of a strain or species in an established microbial 
community  [13–15]  or act as communication molecules in bacterial consortia like biofilms  [11]. 
Nevertheless, using pure bacteriocins is not practical since it has no economic basis. One way to 
substitute antibiotics smartly and sustainably will be the  selection of bacteriocinogenic and   
anti-pathogenic strains from animal-associated bacterial microorganisms for use as probiotics. 
In this review, the first section deals with a definition of probiotics and their mode of action, while 
the second part is dedicated to bacteriocin knowledge to date. Then an inventory of marine bacteriocin-
like inhibitory substances (BLIS) producing bacteria in the literature is drawn up. The last section is 
about an efficient strategy to select bacteriocinogenic bacteria. 
2. Probiotics for Aquaculture 
In 1908 Elie Metchnikoff started the discipline of probiotics by reporting for the first time dietary 
supplements containing potentially beneficial micro-organisms. However, Kollath was the first to Mar. Drugs 2010, 8                       
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suggest, in 1953, the term “probiotics” to designate organic or inorganic substances that are essential to 
a healthy development of life [16]. Two decades later, Parker used the term “probiotic” to describe 
animal feed supplements that contribute to the gut microbial communities of the host [17]. In 1989, 
Fuller suggested another definition widely used since: “A live microbial feed supplement which 
beneficially affects the host animal by improving its intestinal balance” [18]. This revised definition 
differs from Parker’s one by emphasizing the importance of live cells that permit the formal exclusion 
of antibiotics from the probiotics group. In 1999, Salminen proposed a new definition: “Probiotics are 
microbial cell preparations or components of microbial cells that have a beneficial effect on the health 
and well-being of the host” [19]. This implies that non-viable forms of probiotics have also been 
shown to have health effects and should not restrict the utilization of probiotics in food [20]. The 
International Scientific Association for Probiotics and Prebiotics recently adopted the definition of the 
World Health Organization: “Probiotics are live microorganisms which when administrated in 
adequate amounts confer a health benefit on host” [21].  
Nevertheless, none of these definitions fit with aquaculture since aquatic animals have a much 
closer relationship with their environment than terrestrial ones. In fact, in seawater, pathogens 
proliferate independently of the host, so opportunistic organisms can reach a high density around 
aquatic animals  [22]. Furthermore, it is admitted that bacteria present in aquatic environments 
influence the composition of the gut microbiota, with surrounding bacteria being continuously ingested 
[23,24]. The intensive interaction between the environment and the farmed aquatic animals implies 
that the definition of probiotics has to be adapted for aquaculture. Based on this statement, a new 
definition for probiotics has been proposed: “A live microbial adjunct which has a beneficial effect on 
host by modifying the host-associated or ambient microbial community, by ensuring improved use of 
the feed or enhancing its nutritional value, by enhancing the host response towards disease, or by 
improving the quality of its ambient environment” [25]. 
This confers to aquaculture probiotics a large possibility to affect the host health positively [26] by 
competitive exclusion [27], by enzymatic contribution to digestion [11,28,29] and by enhancement of 
the immune response [30,31] or by the production of inhibitory substances [9]. Inhibitory substance 
production is probably one of the most studied modes of probiotic action.  
3. Bacteriocins 
3.1. Bacteriocin story 
To go back to the first bacteriocin descriptions amounts to studying the first works concerning 
bacterial antagonism. Such bacterial antagonism was described by the pioneers of microbiology during 
the last decades of the 19
th  century. At  that  time, the molecular basis of bacterial inhibition was 
abstruse, so it was difficult to distinguish antagonism due to bacteriocins from that provoked by other 
compounds such as antibiotics,  organic acids or  hydrogen peroxide,  except  on the basis of their 
spectrum of activity, usually narrower than that of the other ones. Although Cornil and Babès 
suggested a very narrow antagonism within the genus Staphyloccoccus (“le staphylocoque empêche 
surtout le staphylocoque”) in their 1885  treatise of bacteriology  [32], the scientific community Mar. Drugs 2010, 8                       
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acknowledges the Gratia et al. findings [33] in 1925 as the first documented bacteriocin activity. 
Indeed, it was named colicin V by the same team in 1949 [34] and later microcin V [35].  
The term bacteriocin did not appear until the fifties [34]. This bacteriocin definition is based on the 
properties of the colicins, that is to say, a lethal biosynthesis, a very narrow spectrum of activity 
limited to the same species as the producer bacteria and a receptor-mediated mechanism of action [36]. 
In those days, during the fifties and sixties, the bacteriocin world was mainly made up of bacteriocins 
from Gram negative bacteria  [37,38]. Three genera of Gram positive bacteria were studied for 
bacteriocin production: Bacillus sp., Listeria sp. and Staphylococcus sp., but it should be noted that 
during the first half of the 20th century, two lantibiotics, one of the most famous bacteriocins to date, 
were described. Indeed, the first observations of nisin activity could be those of Roger et al. [39], while 
subtilin was identified in 1944 from Bacillus subtilis [40]. The exotic amino acid sequences of nisin 
and subtilin were only elucidated in the early seventies [41,42].  
The eighties saw an increase in the number of publications on bacteriocin for both colicin type- and 
non colicin bacteriocins (Figure 1). But the attribution of nisin GRAS-status by FDA in 1988 [43] 
would  unleash  interest in  the bacteriocins produced by lactic acid bacteria. Indeed, the industrial 
applications and  the medical and  veterinary potential of these  microorganisms  considered  as 
technological ones are enormous [44–48]. These bacteriocins have aroused a keen interest which has 
resulted in an exponential increase in the number of publications, while scientific publications about 
colicins, which may represent the most extensively studied bacteriocins to date, seem to be stabilizing 
(Figure 1).  
Figure 1. Bacteriocin related publications per 10 years period referenced in Pubmed. The 
bibliographical data bank, Pubmed, was questioned per period of 10 year since 1949. The 
various keywords employed aimed at distinguishing the various categories of bacteriocins. 
They were required in title and summary. The different keywords used for query were 
“Colicin” for colicin, “microcin not colicin” for microcins and “bacteriocin and LAB not 
colicin not microcin” for LAB bacteriocin. 
 
Such interest in LAB bacteriocins has  resulted in applications as food preservatives,  eg 
antimicrobial ingredients [45–50]. Over the last 20 years, 706 patents based on LAB bacteriocins 
activity have been recorded around the World, 421 of which were linked to food preservation, and 124 Mar. Drugs 2010, 8                       
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to animal probiotics (http://www.freepatentsonline.com). The non LAB bacteriocins are not devoid of 
application fields. Applications have also been suggested for plant protection [12,51,52], to prevent 
local infections  in humans  [53]  and recently in aquaculture  [11]. Two dedicated freely available 
bacteriocin online databases have been assembled: BACTIBASE [54] and BAGEL [55]. Moreover, 
bacteriocins are part of antimicrobial peptides and on this account,  are referenced in various 
antimicrobial peptide databases such as APD2 [56,57] or CyBase [58]. 
A new category of bacteriocins  has emerged over the last two  decades:  that of the microcins  
(Figure 1). These may be considered as the “little sisters” of colicins since they exhibit low molecular 
weight and are produced by enterobacteriae (for reviews see [35,59,60]). Besides, most microcins 
exhibit intensive post translational modifications yielding exotic amino acids [61]. In a way, microcins 
are counterparts of lantibiotics in Gram negative bacteria [61].  
Only a few publications are dedicated to bacteriocin production by marine bacteria. Only a few 
BLIS have been described from marine bacteria and a unique bacteriocin has been fully characterized 
(see below). In light  of marine bacterial biodiversity and the urgent requirement for antibiotic 
alternatives, we can assume  that  the  marine bacteriocin category will grow exponentially in the   
near future. 
3.2. Bacteriocin classification 
To date, about two hundred bacteriocins have been characterized (BACTIBASE, BAGEL). 
Bacteriocin classification is not well-established yet and is still the subject of debate. Although dating 
back to 1993, the bacteriocin classification defined by Klaenhammer is still the most cited one [62]. 
An update was proposed by Cotter et al. in 2005 [63] and debated by Heng and Tagg in 2006 [64,65]. 
Bacteriocins are usually  classified combining various criteria. The main  ones  being the producer 
bacterial family, their molecular weight and finally their amino acid sequence homologies and/or gene 
cluster organization. An overview of bacteriocins known to date, proposed in Table 1, shows two main 
categories: the protein-bacteriocins mainly produced by Gracilicutes, mostly enterobacteriae and the 
peptide-bacteriocins from Firmicutes, chiefly from LAB. Even so, this statement needs to be qualified 
since enterobacteriae and LAB were the main bacteria studied for bacteriocin production. Our feeling 
is that peptide bacteriocins from Gracilicutes such as microcins are no exceptions. 
Colicins are protein-bacteriocins  containing about 500–600 amino acid  residues  [66]. They are 
organized in three specific domains. Binding to a specific receptor of the target cell, which is the first 
step of colicin cytotoxic action is governed by the central domain of colicins. The N-terminal and  
C-terminal domains are respectively responsible for colicin translocation and antibacterial activity (for 
a  review see  [67]). They have been classified in two sub-classes, based on cross resistance  [68], 
translocation system, mechanism of release from the producing cell, and size of encoding plasmids 
[69]. Group A, translocated by the Tol system and encoded by small plasmids, is composed of colicins 
A, E1 to E9, K, L, N, S4, U, and Y while group B, translocated by the TonB system and encoded by 
large plasmids, are made up of colicins B, D, H, Ia, Ib, M, 5, and 10.  
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Table 1. Bacteriocin overview. 
(A) 
Protein-Bacteriocins   Class  Sub-Class   Name  MM (kDa)  Mode of action   Ref. 
Gracilicutes 
            Escherichia coli   Colicins  Groupe A 
 
40 to 80  Nuclease/Pore-forming   [69] 
   
Groupe B 
 
40 to 80  Nuclease/Pore-forming   [69] 
Pseudomonas aeruginosa  Pyocins  R-type  Pyocin R2  270 (AA)  Pore-forming 
 
   
S-type  Pyocin S1,S2,AP41  75/84/94  Phage-tail like   [70] 
   
F-type  Pyocin F 
 
Phage-tail like 
  Hafnia alvei  Alveicins  Colicin like  Alveicin A, B  408/358 (AA)  Pore forming   [71] 
Klebsiella pneumonia  Klebicin  Colicin-like  Klebicin C, D  96  Nuclease   [72,73] 
Serratia plymithicum  Serracin 
 
Serracin P  66  Phage-tail like   [74] 
Xanthomonas campestris  Glynericin 
 
Glynericin A  50  Phage tail like   [75,76] 
Yersinia enterocolitica  Enterocoliticin 
   
669  Phage tail like   [77] 
Erwinia carotovora  Carotovoricin 
 
Carotovoricin Er  68/76  Phage tail like   [78] 
Firmicutes 
            Lactobacillus helveticus  Helveticin J  Class III 
 
37,5  to be defined   [79] 
Streptococcus milleri  Millericin  Class III 
 
30  Peptidoglycan hydrolysis   [80] 
Enterococcus faecalis   Enterolysin  Class III 
 
34,5  Peptidoglycan hydrolysis   [81] 
Staphylococcus aureus  Lysostaphin  Class III  
 
25  Peptidoglycan hydrolysis   [82,83] 
(B) 
Peptide-Bacteriocin  Class  Sub-Class 
 
Name  MM (kDa)  PTM  Mode of action  Ref. 
Gracilicutes 
               
Escherichia coli  Microcin  Class I 
 
Microcin B17  3.1  drastic 
intracellular 
enzymes 
 
   
Class II  IIa  Microcin V  8.8  light  pore-forming   [35,59,61] 
     
IIb  Microcin E492  7.9  drastic  pore forming   
Firmicutes 
               
Lactic acid bacteria  Class I  A-type  A1  Nisin  3.5  drastic  pore-forming   [84,85] 
(mainly)  or Lantibiotic 
 
A2  Lacticin 481  3  drastic  pore forming   [86] 
   
B-type 
 
Mersacidin  2 
   
 [61] 
 
Class II  class IIa 
 
Pediocin  4.6  light  pore forming   [48,87] 
   
class IIb 
 
Plantaricin E/F  3.5/3.7  light  pore forming   [88] 
   
Class IIc 
 
carnocyclin A  5.8  cyclic  pore forming   [89,90] 
   
Class IId 
 
Lactococcin A  5.8  none  pore forming   [91] 
Cyanobacteria 
               
Prochloron didemni  microcin –like  - 
 
Patellamides  0.7  drastic 
 
 [92] 
Ref., PTM, AA and ref. respectively mean Review reference, Post-translational modification and amino acids. Mar. Drugs 2010, 8                       
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Both groups act on sensitive cells by targeting either the inner membrane by pore formation or an 
intracellular target using enzymatic activity such as DNAse or RNAse  [67]. Bacteriocins of such 
molecular weight are exceptions in Firmicutes compared with the colicin family. Only two have been 
described in LAB [79,80]. Such protein-bacteriocins produced by LAB have been named class III 
bacteriocins. The others are specific of  Bacillus megaterium  [93],  Enterococcus faecalis  [81]  or 
Staphylococcus aureus [82].  
The peptide-bacteriocin group is produced by Gracilicutes and Firmicutes as well. Until 2007, the 
microcin group was composed of two classes, based on their post-translational modifications [94]. 
According to their gene cluster organization, this classification has recently evolved [35,59] to give 
birth to two main classes and two sub-classes. Class I comprises the smallest microcins with molecular 
masses ranging from 1.1 kDa to 3 kDa (Table 1). They display drastic post-translational modifications 
leading to exotic structures such as thiazole and oxazole rings in MccB17 (Figure 2). This class acts on 
sensitive cells by interaction with an intracellular target such as DNA gyrase inhibited by MccB17 
[95]. The second microcin class is divided into two sub-classes. The microcin class IIa bridges the gap 
between colicin and microcin since these peptides are bigger (about 8 kDa) than a typical microcin and 
exhibit no modifications with the exception of a  single disulfide bond formation. One of them, 
Microcin V (MccV) was previously called colicin V  [35], the first documented bacteriocin  [33]. 
Nevertheless, its gene cluster organization connects them undoubtedly to the microcin family [35]. 
Unlike previous microcins, class IIb microcins are chromosomally encoded, lacking disulfide bond, 
exposing a conserved serine-rich C-terminal and carrying for some of them a siderophore-type part 
(MccE492). MccE492 carries out its antibacterial activity by membrane permeabilization. But it was 
shown to target inner membrane proteins belonging to the mannose permease family [96]. 
The other main peptide bacteriocins family is the LAB one. Indeed, of the two hundred or so 
bacteriocins described to date, almost 90% are from LAB. With the exception of Helveticin J [79] and 
Milletricin [80], which are members of class III bacteriocins, they all are of peptidic nature. They have 
been divided into two main classes: class I and class II, the latter in turn containing three sub-classes  
(Table 1). 
Lantibiotics have been defined as class I. Lantibiotic peptides undergo drastic posttranslational 
modification leading to unusual amino acid residues such as lanthionine. In a way, they are the 
counterpart of microcins in Firmicutes. To date, about 50 different lantibiotics have been described in 
LAB and non LAB bacteria such as Staphylococcus aureus [97]. Overall, lantibiotics are divided on 
the basis of their topology, that is to say their lanthionine bridge arrangements. Type-A lantibiotics 
such as nisin (Figure 2) are linear and cationic peptides, while type-B ones are globular [86,98]. The 
former exerts its antibacterial activity by membrane permeabilization by pore formation in a torroid 
manner  [98]  after binding to lipid II,  while the latter targets intracellular enzyme function  [98]. 
Another emerging lantibiotic class is the two-component lantibiotics such as haloduracin [99–101].  
Class II bacteriocins are lightly modified peptides. These peptides are 20 to 70 amino acid residue-
long. Extensive studies have been carried out about their mechanism of action. It has appeared that 
they use a common global procedure targeting a membrane-embedded domain of an integrated 
membrane protein  [91]. The conformational modifications resulting from membrane protein–
bacteriocin interactions lead to membrane perturbations, permeabilization and finally bacterial cell 
death [102]. It was divided into four sub classes on the basis of their activity. Class IIa was also named Mar. Drugs 2010, 8                       
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pediocin-like or anti-Listeria  bacteriocins since all of them displayed antibacterial activity against 
Listeria  spp.  [62]. These bacteriocins are peptides sharing a highly conserved  N-terminal part 
harboring a consensus sequence:  -Y-Y-G-N-G-V-X-C-x-x-x-x-C (Figure 2) where C residues are 
involved in a  disulfide bridge  [48]. Their more variable C-terminal part has been used for their 
segregation in four sub-groups [63,102]. They act on target cells by a pore-forming mechanism of 
action [48,87,102]. This class constitutes the bacteriocin success story of the last twenty years. Class 
IIb is an original antimicrobial peptide class because it is made up of two independent peptides, each 
being active but both being required for optimal activity [102]. Around twelve such two-component 
bacteriocins have been described in LAB. Each time, the most active mix was obtained with equivalent 
concentration of each peptide [88]. LAB bacteriocin group IIc are real cyclic peptides since their N- 
and C-termini are covalently connected (for review, the reader is referred to [63,89]). Their mechanism 
of action when explored was permeabilization of the inner membrane of target cells leading to cell 
death. Finally, unmodified and non-pediocin-like peptides and single peptide active bacteriocins form 
class IId. To date, about 32 different class IId peptides have been described [102].  
3.3. Bacteriocin specificity 
Bacteriocins are unique antimicrobial peptides. Indeed, the producing strain has to protect itself 
from its own peptides, so bacteriocin-producing bacteria have to develop some sort of immunity 
strategy. In addition to a structural gene, post-translational gene and export machinery, the gene cluster 
organization of bacteriocin encodes as well for an immunity protein. The latter ensures bacteriocin 
protection in various ways, depending on the bacteriocin mechanism of action.  
Immunity to pore forming colicins is mediated by a 11 to 18 kDa small membrane protein. A direct 
and specific interaction within the inner membrane between the immunity protein and the C-terminal 
part of colicin achieves cell protection. Transmembrane helices have been shown to be the main motifs 
recognized by immunity proteins. Colicins targeting intracellular enzymes  such as nuclease are 
inactivated by direct binding of the immunity protein (about 10 kDa) to the active domain of colicin 
leading to a 71-kDa heterodimer. 
Microcin immunity still remains opaque, while that towards lantibiotic has been recently reviewed 
[103,104]. Lantibiotic immunity is conferred by lipoprotein intercepting lantibiotic at the cytoplasmic 
membrane and/or ABC transporter–type membrane protein complex. Immunity to class II bacteriocins 
produced by  LAB has recently been cleared up  [91]. It implies that  components of the mannose 
phosphotransferase system are receptors for both bacteriocin and the imunity protein [105]. To define 
the role of bacteriocins in producing bacteria is still a challenge. Its production entails advantages in 
colonizing or defending ecological niches for producing bacteria.  
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Figure 2. Covalent structure of some representative peptide-bacteriocins. A: nisin, B: 
microcin B17, C: pediocin PA-1, D patellamide A. 
 
4. Marine Animal-Associated Microorganisms as Bacteriocin Producers 
Marine animal-associated micro-organisms have been recently studied. Various authors have shown 
that these bacteria belong to the genera Vibrio, Pseudoalteromonas, Aeromonas, Alteromonas, and to 
the Cytophaga- Flavobacterium- Bacteroides group [106,107]. Currently, there are relatively few reports 
in the literature of antibacterial peptide or proteins produced by marine bacteria that have identified 
step sequence/structure. Wilson et al. [107] have isolated eight marine bacteria which produced anti-
bacterial substances from a variety of different marine invertebrates (oysters, barnacles, sponges, 
tunicates, sea urchins, seaweeds). The loss of activity, after proteolytic digestion of their extracts, has 
suggested a proteinceous nature. 
An increasing number of compounds with antibacterial activity have been found to be produced by 
a variety of organisms present in the marine surface environment. Potentially, there are many cases in 
which products previously attributed to higher organisms may be produced by their associated 
microorganisms  such as patellamide  [92]. Finally, numerous studies have  evaluated  antimicrobial Mar. Drugs 2010, 8                       
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marine isolates from sponge, coral, alga and mollusc associated bacteria [106–108]. Nevertheless, only 
a few studies have focused on marine bacterium isolation from marine animals and the search for their 
ability to produce bacteriocins (Table 2).  
4.1. BLIS from Vibrio sp. 
Vibrio species are ubiquitous in the marine environment and are commonly isolated from fish and 
shellfish specimens [109]. Some species may be pathogenic to marine life, but some do not appear to 
affect them. Due to their capability to occupy this ecological niche they have been studied for their 
capacity to produce bacteriocin-like inhibitory substances (BLIS). Zai et al. [110] have isolated and 
identified fifty strains of the genus Vibrio isolated from the gills and gut region of healthy and infected 
catfishes (Arianus thalassinus). BLIS was detected and called Vibriocin AVP10 (Table 2). 
Fresh and frozen seafood were studied by Carraturo et al. [111]. They have isolated three non-
pathogenic (for humans) species of Vibrio (V. mediterranei 1,  V. mediterranei 4 and V. fluvialis) 
displaying antagonistic activity on solid agar medium against pathogenic V. parahaemolyticus and V. 
mediterranei. A partial purification of a BLIS produced by V. mediterranei  1 was reported. Its 
proteinaceous nature was revealed by enzymatic degradation by proteinase K. Thanks to size exclusion 
chromatography, Carraturo et al. [111] have purified an antimicrobial fraction whose molecular mass 
was determined by SDS-PAGE to be 63–65 kDa corresponding to a mixture of unrelated polypeptides, 
including the bacteriocin. 
Furthermore, V. harveyi is a serious pathogen of many vertebrate and invertebrate marine animals 
[112,113]. McCall and Sizemore [114] have reported for the first time the production of a bacteriocin 
in a strain of Beneckea harveyi (V. harveyi). The bacteriocin, ‘harveyicin SY’, with an estimated 
molecular mass of 24 kDa, was lethal to two strains of V. harveyi, KN96 and BBP8   
(Table 2).  Harveyicin SY was susceptible to proteolytic enzymes, and is  apparently plasmid   
associated [114,115].  
Prasad et al. [112], whilst screening various V. harveyi isolates from their culture collection have 
recognized a possible BLIS production by a strain of V. harveyi (VIB 571). Interestingly, this strain 
has been demonstrated to be pathogenic to rainbow trout (Oncorhynchus mykiss) and Atlantic salmon 
(Salmo salar) [113].  
Inter-strain and inter-species inhibition mediated by a bacteriocin-like inhibitory substance (BLIS) 
from V. harveyi VIB 571 was demonstrated against four isolates of the same species and V. fischeri, V. 
gazogenes and V. parahaemolyticus (Table 2). The crude BLIS, which was obtained by ammonium-
sulphate precipitation of the cell-free supernatant of a 72 h broth culture, was inactivated by lipase, 
proteinase K, pepsin, trypsin, pronase E and SDS. Incubation for 10 min at more than 60 °C resulted in 
loss of activity. On the other hand, antibacterial activity was not affected by pH. Anion-exchange 
chromatography, gel filtration, SDS-PAGE and two-dimensional gel electrophoresis revealed the 
presence of a single major peak, comprising a protein with a pI of ~5.4 and a molecular mass of  
~32 kDa (Table 2). The N-terminal sequencing of the ~32 kDa protein yielded: D-E-Y-I-S-X-N-K-X-
S-S-A-D-I where ‘X’ may be cystein or modified amino acid residues.  
Other vibriocins were isolated by Shehane  and  Sizemore  [116]. Their aim was to identify 
bacteriocins effective against V. vulnificus in seafood. Isolates from estuaries near Wilmington (NC, Mar. Drugs 2010, 8                       
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USA) containing plasmids were checked for antimicrobial activity which was not due to lytic 
bacteriophage or small, non specific molecules. Three bacteriocin producers of V. vulnificus were 
detected and their inhibitory spectra determined (Table 2). Strain IW1 inhibited few strains of V. 
vulnificus; BC1 inhibited several strains of V. vulnificus, V. cholerae and V. parahaemolyticus and 
BC2 inhibited all tested Vibrio spp, Plesiomonas shigelloides and E. coli. Loss of inhibitory activity 
coincided with loss of the bacteriocinogenic plasmid. The molecular weights of the bacteriocins were 
estimated to be 9.0 kDa for IW1, 7.5 kDa for BC1 and 1.35 kDa for BC2 thanks to size exclusion 
chromatography. IW1 was heat labile,  while BC1 was moderately stable except at extreme 
temperatures. BC2 was very stable and maintained its activity when frozen, autoclaved or exposed to 
extreme pH values [116]. The authors suggested that these bacteriocins might provide a tool for the 
removal of V. vulnificus from seafood. 
Strain Vibrio sp. NM 10 was isolated from spotnape ponyfish (Leiognathus nuchalis) collected in 
coastal regions of Enoshima Island, Kanagawa, Japan. This strain exhibited high activity against P. 
piscicida K-III, but was also able to inhibit E. coli IAM 1264, V. vulnificus RIMD 2219009 and 
Enterococcus seriolicida YT-3 [117]. The antibacterial substance produced by Vibrio sp. NM 10 is a 
proteinaceous heat-labile substance with a molecular mass of less than 5 kDa. These facts strongly 
suggest that the antibacterial substance is either a bacteriocin or a bacteriocin-like substance [117]. 
4.2. BLIS from marine Aeromonas sp. 
Authors Moro et al. [118] and Messi et al. [119] have shown their interest in evaluating BLIS 
production in Aeromonas hydrophila. All strains of  Aeromonas hydrophila  in these two studies 
demonstrated inhibitory activities against several strains of Staphylococcus aureus (Table 2). Messi et 
al. [119] have demonstrated further inhibitory effect against Listeria species, Streptococcus agalactiae 
and Lactobacillus sp. No inhibition was observed against all Gram-negative strains assayed, including 
related species (Aeromonas sobria  ATCC 43979, A.  caviae  ATCC 13137). Such an inhibitory 
spectrum is not compatible with the bacteriocin definition.  
Table 2. Bacteriocins produced by bacteria isolated from marine environment. 
Producing strain  Bacteriocin  Inhibited strain(s)  Isolated from  MM (kDa)  Ref. 
Listonella anguillarum AVP10  Vibriocin AVP10 
Escherichia coli 
Listonella anguillarum AVS9
1 
Healthy and infected 
catfishes 
(Arius thalassimus) 
?   [110] 
Vibrio mediterranei  BLIS 
V. parahaemolyticus 
V. mediterranei 5 
Fresh & frozen 
seafood 
63–65
a   [111] 
Vibrio harveyi VIB 571  BLIS 
Vibrio harveyi
1 
V. fischeri  
V. gazogenes  
V. parahaemolyticus  
-  ~32
a,b   [112] 
Vibrio harveyi (Beneckea 
harveyi SY) 
Harveyicin SY  V. harveyi
1 
area of Galveston 
Island 
24   [114,115] 
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Table 2. Cont. 
Vibrio vulnificus 
IW1 
V. vulnificus 
V. cholera 
Water samples from 
Wilmington  
(NC, USA) 
 
9 
 
 
7,5 
 
 
1,35 
 [116] 
BC1  V. parahaemolyticus 
BC2 
Vibrio spp. 
Plesiomonas shigelloides 
E. coli 
Vibrio sp. Strain NM 10  BLIS 
Pasteurella piscicida K-III; 
E. coli; 
V. vulnificus 
Enterococcus seriolicida 
Leiognathus nuchalis 
intestine 
< 5 
d   [117] 
Bacteriocinogenic strain 
marine strain ZM81 (Gram 
positif pleomorphic strain) 
Bacteriocins/ BLIS  Marine bacterial strain ZM19  
Open sea region of 
Karachi coast 
>10   [120] 
Aeromonas hydrophila  BLIS  Staphylococcus aureus strains 
Water tank 
containing alligators 
? 
 [118] 
 [119] 
Pseudoalteromonas Species 
Strain X153 
 
Antibiotic protein 
P-153 
Ichthyopathogenic Vibrio
1 
Staphylococcus epidermidis 
Propionibacterium acnes  
Propionibacterium granulosum 
Substrates on the 
littoral of Brittany 
280
a,b   [121] 
Molecular mass was evaluated using sodium dodecyl sulfate polyacrylamide gel electrophoresis
  a; size-exclusion 
chromatography
  b, Mass Spectrometry
  c  or ultrafiltration
d. 
1: aquacole pathogen. 
2: bacteriocin isolated from fish 
intestine. ?: Unknown molecular mass.  
4.3. BLIS from marine Pseudoalteromonas sp. 
Longeon  et al.  [121]  investigated bacteria collected from different substrates on the littoral of 
Brittany and they focused their attention on a Pseudoalteromonas sp. named X-153 that exhibited high 
antimicrobial activity. Purification of the active protein P-153 from the bacterial cells was achieved. 
This antibacterial protein was evaluated by size exclusion chromatography to be of 280 kDa size. This 
antibacterial protein was shown to be active against both gracilicutes (ichthyopathogenic Vibrio) and 
firmicutes (Staphylococcus epidermidis, Propionibacterium acnes and P. granulosum) (Table 2). Such 
a broad spectrum of activity is not consistent with the definition of a bacteriocin. 
4.4. Bacteriocin from Firmicutes and LAB associated to marine animals 
It is generally considered that Gram-positive bacteria, including lactic acid bacteria, are numerically 
dominant members of the normal microbiota in the gastrointestinal tract of endothermic animals at an 
early stage of their lives [122]. The gastrointestinal microbiota of healthy fish is usually composed of 
lactic acid bacteria belonging to the genera Streptococcus, Lactobacillus, Carnobacterium, 
Leuconostoc  [122]. Divercins and piscicocins have been fully characterized from Carnobacterium 
isolated from fish intestine (Table 3). These two bacteriocins belong to class IIa of bacteriocins 
produced by LAB (see Table 1, for review the reader is referred to [123]). Mar. Drugs 2010, 8                       
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In 2004, Pirzada et al. [120] isolated and studied a bacteriocinogenic strain ZM81, a Gram positive 
pleomorphic rod, which was isolated from the open sea region of Karachi. The proteinaceous nature of 
the cell-free supernatant of marine strain ZM81 was defined by enzyme degradation with pronase and 
trypsin. Fractionization of the crude bacteriocin thanks to a molecular weight cut-off membrane 
showed an enrichment of activity in the fraction containing >10 kDa bacteriocin-like inhibitory 
substance. BLIS produced by Marine Bacterium ZM81 is heat labile and exhibits activity within a 
wide pH range of 4–12 [120].
 
Table 3. Bacteriocin produced by Lactic Acid Bacteria isolated from marine animal. 
Producing strain  Bacteriocin  Inhibited strain(s)  Isolated from  MM (kDa)  Ref. 
Enterococcus faecium 
LHICA 28.4, 34.5, 40.4, 46 
Enterocin P 
Carnobacterium maltaromaticum 
Listeria monocytogenes 
Staphylococcus aureus 
Turbot muscle     [124] 
Enterococcus faecium ALP7  bac ALP7  Listeria monocytogenes 
Non-fermented 
shellfish including 
oysters, mussels and 
clams 
<10   [125] 
Pediococcus pentosaceus 
ALP57 
bac ALP57 
Bacillus subtilis  
Enterococcus faecalis  
Lactobacillus brevis gravensis; 
Lactobacillus curvatus 
Listeria innocua 
Carnobacterium divergens 
V41 
Divercin V41  Listeria monocytogenes  Salmon intestine  4,509   [126–129] 
Carnobacterium piscicola 
V1 
Piscicocin V1a 
Piscicocin V1b 
Listeria monocytogenes  Trout intestine 
4,416 
4,526 
 [128,130] 
4.5. Bacteriocin from marine cyanobacteria 
While most small peptides found in Cyanobacteria are biosynthesized by nonribosomal peptide 
synthetases [131], a microcin-like pathway for the biosynthesis of a family of cyclic peptides, the 
patellamides (Figure 2), has been recently reported in Prochloron didemni, a cyanobacterial symbiont 
of tropical  ascidians  [92]. The patellamides are moderately cytotoxic and composed of a 
pseudosymmetrical, cyclic dimer, with each substructure having the sequence thiazole-nonpolar amino 
acid-oxazoline-nonpolar amino acid. Despite these unusual features, patellamide  biosynthesis is 
ribosomal [132]. The discovery of patellamides has provided first insight into the biosynthesis of 
microcin-like peptide distribution and versatility in Cyanobacteria [133]. 
The patellamide family are cyclic octapeptides (Figure 2) characterized by the presence of thiazole 
and oxazole moieties. Although nonribosomal biosynthesis was anticipated for the formation of these 
peptides, heterologous expression of a microcin-like gene cluster discovered in the genome of the 
cyanobacterium Prochloron didemni unambiguously showed that these peptides are produced by a 
ribosomal pathway  [92,133,134].  An increasing number of other  cyclic peptides containing Mar. Drugs 2010, 8                       
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heterocyclic amino acids has recently been isolated from planktonic and other  animal-associated 
cyanobacteria, including nostocyclamide  [135], tenuecyclamides  [136], venturamides  [137], 
dendroamides [138], and microcyclamides [139]. The variety of structures is reflected in an equally 
large variety of bioactivities, such as antibacterial, cytotoxic, and antimalarial activities [133]. 
5. Bacteriocin-Based Strategy to Select a Probiotic for Aquaculture 
In animal or human nutrition, lactic acid bacteria largely dominate the worldwide probiotic market. 
Actually, they have demonstrated their safety and efficiency over a  century. Aquaculture is no 
exception. Indeed most probiotics used in aquaculture belong to the LAB (for a review the reader is 
referred to [140,141]). Bacillus genus has also been successfully used in aquaculture [142] makes the 
list longer by adding marine bacteria belonging to Aeromonas, Pseudomonas, Pseudoalteromonas, 
Roseobacter  and  Vibrio  and a yeast,  Saccharomyces cerevisiae  [143].  Moreover, the potential of 
marine actinobacteria as probiotics in aquaculture has been recently reviewed [144]. All the same, 
marine bacteria are much less developed as a probiotic source in spite of promising results [143,144]. 
This may be due to a dissuasive legislation.  
The use of probiotics in aquaculture is closely controlled by the administration. In the European 
Union, probiotics are controlled by regulation CE n°1831/2003 (OJ L 268 of 18.10.2003) on the use of 
additives in animal food. Industrialists have to obtain an authorization from the European Food Safety 
Authority (EFSA), which controls the beneficial effects of probiotics on animal and human health 
safety and the environment. The safety assessment of microorganisms is in a guideline issued by a 
relevant scientific committee (SCAN) in 2001. Several specific tests and studies have to be carried out 
in order to obtain the QSP (Qualified Presumption of Safety) [145]. In the US, probiotics which are 
used in animal feed are called “direct fed microbials” and are  regulated by the Food and Drug 
Administration. The efficacy and safety of probiotics are examined by the FDA, which can recognize 
the microorganism as safe (Generally Recognised As Safe). The GRAS-status can be obtained in two 
ways:  some  microorganisms have a  long history  of  safety  (find them at 
http://www.cfsan.fda.gov/~dms/opa-micro.html.) or have been recognized by qualified experts as safe 
under the conditions of intended use [145]. The GRAS concept means that responsibility for safety of 
the products resides strictly with the producer. To obtain probiotic authorization, the manufacturer has 
to send a petition to the FDA and the general requirements for this petition are detailed in the US Code 
of Federal Regulations [146]. 
We advocate a strategy aiming at preventing establishment of pathogenic bacteria using probiotics. 
These should be selected from natural indigenous microbial communities  associated with marine 
animals. Bacteriocins are efficient weapons to protect and thus to defend an ecological niche or a 
nutrient pool. Indeed these peptides combine the most potent activity of related bacteria and a specific 
spectrum of activity [45]. Thus they constitute a pertinent tool to select a probiotic. So we propose a 
strategy for probiotic selection based on bacteriocin production ability (Figure 3). 
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Figure 3. Strategy to select probiotics for aquaculture. 
 
The first step of selection is to screen the animal-associated micro-organisms for antagonistic 
activities against the selected target cells. This acquisition is one of the major phases of assessment of 
potential probiotics [147]. Probiotic bacteria for use in aquaculture have to be isolated from indigenous 
or exogenous microbiota of aquatic vertebrates or invertebrates [27] in order to facilitate establishment 
and efficiency over temperature and salinity variations of aquaculture farming [144]. This selection is 
generally carried out by using in vitro antagonist tests [25,144]. Then two ways are possible: the use of 
the inhibitory compounds as an antibiotic or that of bacteria as probiotics (Figure 3). For the former, 
research has to be carried out in order to determine the nature of inhibitory compounds, the mode of 
action, and the genetic aspect of BLIS. However, the administration of purified bacteriocins does not 
appear to be a cost-effective approach. In face of this need, the second alternative seems to be a more 
feasible approach. When the putative probiotic is selected, the research has to focus on two parts: the Mar. Drugs 2010, 8                       
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evaluation of safety and the beneficial effects under rearing conditions [147]. Safety has to be proved 
under in-vivo and rearing conditions for the host of course, but also for the environment. Then the 
commercial procedures can be submitted to the authorities concerned.  
It is important to note that probiotics producing antagonistic compounds have to be used in a 
preventive way [148]. Indeed, a review [149] showed that BS107 (a marine bacteria identified as 
Roseobacter) cannot be used for treatment when the pathogen is in sufficient concentration to provoke 
a  disease outbreak. In fact, the  authors demonstrate that BS107 (10
6  cells/mL) doesn’t have any 
probiotic activity when living cells are co-inoculated with Vibrio pectenicida A496 (10
4 cells/mL).  
6. Conclusions 
Bacteriocins from LAB have demonstrated their remarkable potential as food conservatives  
[13,44–50,63,87,123], or as therapeutics for veterinary or medical uses [13,53] or as phytosanitary for 
plant protection [51]. Extensively studied in LAB and enterobacteriae, little or nothing is known of 
marine bacteriocins. Only a few have been described, and the fully-characterized ones are exceptions, 
so knowledge of marine bacteriocins is at the early stages. 
Moreover, the increasing scarcity of marine resources ensures a rise in aquaculture in the next 
decades but also condemns it to set up effective strategies respectful of the environment. In this 
context, marine bacteriocins that are produced by LAB or autochthonous associated marine bacteria 
seem to be a relevant alternative to antibiotics. Based on both bacteriocin diversity described to date 
and the ocean microbial biodiversity, one can predict the discovery of a true peptide arsenal in the 
coming years. Such an arsenal will find applications in aquaculture. Indeed, the antibiotic approach has 
to be redrawn. The approach that we recommend rests on different concepts: (i) the most effective 
strategy to limit epizooties consists in avoiding contact between host and pathogen; (ii) to eradicate 
pathogenic bacteria is illusory, it’s better to occupy its ecological niche (iii) in the case of infections, it 
is preferable to use active ingredients with a narrow spectrum of antibacterial activity so as to better 
target the pathogenic ones and limit the risk of resistance development. Bacteriocins are perfect tools 
to select as probiotics to apply this strategy. One can dream of protective probiotics made up of several 
BLIS-producing bacteria acting synergistically against pathogens.  
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